Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.36 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.36 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.36 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.36 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.35 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL123712 | 0.82 | HDAC1 (0.52) | HDAC1HDAC6KDM4EMAPTALDH1A1 | |
| SCHEMBL11625027 | 0.80 | HDAC1 (0.50) | HDAC1HDAC6KDM4EMAPTADRA2A | |
| SCHEMBL17033581 | 0.80 | HDAC1 (0.50) | HDAC1HDAC6KDM4EMAPTALDH1A1 | |
| SCHEMBL30544993 | 0.77 | HDAC1 (0.62) | HDAC1HDAC6KDM4EMAPTALDH1A1 | |
| SCHEMBL7948362 | 0.77 | HDAC1 (0.52) | HDAC1HDAC6KDM4EMAPTALDH1A1 | |
| SCHEMBL181465 | 0.77 | HDAC1 (0.62) | HDAC1HDAC6KDM4EMAPTALDH1A1 | |
| SCHEMBL13864292 | 0.77 | HDAC1 (0.52) | HDAC1HDAC6KDM4EADRA2AADRA2B | |
| SCHEMBL21004360 | 0.77 | HDAC1 (0.61) | HDAC1HDAC6KDM4EMAPTADRA2A | |
| SCHEMBL2659565 | 0.77 | HDAC1 (0.52) | HDAC1HDAC6KDM4EMAPTADRA2A | |
| SCHEMBL9504571 | 0.76 | HDAC1 (0.60) | HDAC1HDAC6KDM4EMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102731374-B | Improved process for preparing 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone, an intermediate of etoricoxib | ITALIANA SINT SPA | 2015-05-06 | — | — | CN | disclosed |
| US-8664402-B2 | Process for preparing 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone, an intermediate of etoricoxib | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2014-03-04 | — | — | US | disclosed |
| US-8664402-B2 | Process for preparing 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone, an intermediate of etoricoxib | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2014-03-04 | — | — | US | disclosed |
| US-8664402-B2 | Process for preparing 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone, an intermediate of etoricoxib | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2014-03-04 | — | — | US | disclosed |
| EP-2497767-B1 | Improved process for preparing 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone, an intermediate of etoricoxib | ITALIANA SINT SPA (IT) | 2013-05-29 | — | — | EP | disclosed |
| EP-2497767-B1 | Improved process for preparing 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone, an intermediate of etoricoxib | ITALIANA SINT SPA (IT) | 2013-05-29 | — | — | EP | disclosed |
| CN-102731374-A | Improved process for preparing 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone, an intermediate of etoricoxib | ITALIANA SINT SPA | 2012-10-17 | — | — | CN | disclosed |
| US-20120232281-A1 | PROCESS FOR PREPARING 1-(6-METHYLPYRIDIN-3-YL)-2-[4-(METHYLSULFONYL)PHENYL]ETHANONE, AN INTERMEDIATE OF ETORICOXIB | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2012-09-13 | — | — | US | disclosed |
| US-20120232281-A1 | PROCESS FOR PREPARING 1-(6-METHYLPYRIDIN-3-YL)-2-[4-(METHYLSULFONYL)PHENYL]ETHANONE, AN INTERMEDIATE OF ETORICOXIB | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2012-09-13 | — | — | US | disclosed |
| US-20120232281-A1 | PROCESS FOR PREPARING 1-(6-METHYLPYRIDIN-3-YL)-2-[4-(METHYLSULFONYL)PHENYL]ETHANONE, AN INTERMEDIATE OF ETORICOXIB | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2012-09-13 | — | — | US | disclosed |
| EP-2497767-A1 | Improved process for preparing 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone, an intermediate of etoricoxib | F.I.S. Fabbrica Italiana Sintetici S.p.A. (IT) | 2012-09-12 | — | — | EP | disclosed |
| EP-2497767-A1 | Improved process for preparing 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone, an intermediate of etoricoxib | F.I.S. Fabbrica Italiana Sintetici S.p.A. (IT) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011095997-A1 | BENZAMIDE COMPOUNDS AS GLUCOKINASE ACTIVATORS AND THEIR PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2011-08-11 | — | — | WO | disclosed |
| WO-2008040934-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232281-A1 | PROCESS FOR PREPARING 1-(6-METHYLPYRIDIN-3-YL)-2-[4-(METHYLSULFONYL)PHENYL]ETHANONE, AN INTERMEDIATE OF ETORICOXIB | EEF2K, PTGES, EIF2AK1 | HDAC1 3426/4885HDAC6 4267/4885KDM4E 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.